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SUMMARY
Eosinophil disorders and related syndromes are a hetero-
geneous group of conditions characterized by marked persistent
blood eosinophilia and involvement of one or more organ
systems. The hypereosinophilic (HE) state is deﬁned by
a persistent eosinophil count exceeding 1.5 · 109/L blood.
Several different neoplastic, paraneoplastic, infectious, and aller-
gic disorders may underlie HE. Eosinophil-induced organ dam-
age with more or less typical symptoms may develop in these
patients. The ﬁnal diagnosis is based on clinical, molecular, and
histopathologic criteria, and the presence of signs and symptoms
indicative of HE-induced organ damage, the latter often mani-
festing as hypereosinophilic syndrome. The clinical course,
prognosis, and response to certain drugs vary greatly among
patients and among disease variants. During the last few years,
several new markers and targets have been identiﬁed, improving
diagnosis, prognostication, and therapy for patients with HE-
related disorders. Moreover, several attempts have been made
to establish robust disease-related criteria and a global classi-
ﬁcation for HE-related diseases. However, the pathogenesis
and mechanisms of HE and of HE-induced organ damage
are complex, and expert opinions remain divided.
In light of the increasing burden of allergic diseases, the
World Allergy Organization; the American Academy of
Allergy, Asthma & Immunology; the European Academy of
Allergy and Clinical Immunology; and the American College
of Allergy, Asthma & Immunology have come together to
increase the communication of information about allergies
and asthma at a global level. Within the framework of this
collaboration, termed the International Collaboration in
Asthma, Allergy and Immunology, a series of consensus
documents called International Consensus ON (ICON) are
being developed to serve as an important resource and sup-
port physicians in managing different allergic diseases.
This ICON provides an updated proposal for a global
nomenclature and classiﬁcation of HE-related disorders and
conditions. The proposal is based on the currently available
literature and merges previously published proposals and the
classiﬁcation proposal of the World Health Organization.
The International Collaboration in Asthma and Allergy
initiated an international coalition among the American
Academy of Allergy, Asthma & Immunology; European
Academy of Allergy and Clinical Immunology; World
Allergy Organization; and American College of Allergy,
Asthma and Immunology on eosinophilic disorders. An
author group was formed and then divided into individual
committees. Within the committee, teams of authors were
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Content was derived from literature searches, relevant pub-
lished guidelines, and clinical experience. After a draft of the
document was assembled, it was collectively reviewed and
revised by the authors. Where evidence was lacking or con-
ﬂicting, the information presented represents the consensus
expert opinion of the group.
PROPOSED NOMENCLATURE AND REVIEW OF
THE LITERATURE
The published literature was screened for terminolo-
gies, nomenclatures, criteria, classiﬁcation proposals, and key
information concerning incidence, prevalence, and prognos-
tication of eosinophil disorders. Key publications are refer-
enced. Whenever found, controversies and difﬁculties in
nomenclatures and classiﬁcations were reviewed and dis-
cussed. In this way, the current International Consensus ON
(ICON) article attempts to adhere to the principles of previous
(traditional) classiﬁcations, including World Health Organi-
zation (WHO) criteria for eosinophilia-associated hematopoi-
etic neoplasms. In addition, a recent proposal of the
“International Cooperative Working Group on Eosinophil
Disorders” (ICOG-EO) was used as the basis for the formu-
lation of the ICON document. The ICOG-EO was established
in 2011 as an interdisciplinary network, including representa-
tives from the ﬁelds of allergy, immunology, pathology,
hematology, infectious diseases, and molecular medicine.
Traditionally, the hypereosinophilic syndrome
(HES) has been described as a condition associated with
marked persistent peripheral blood eosinophilia, organ
damage, and exclusion of an underlying disease or
condition that could otherwise explain eosinophilia or organ
damage.
1–5 The plural form (ie, HES) was subsequently pro-
posed to reﬂect the extremely heterogeneous conditions ulti-
mately resulting in eosinophil-mediated organ involvement.
A rare familial type of HES has also been described. As per
the ICOG-EO, HES has been redeﬁned as any form of HE
(not just idiopathic) associated with organ damage. Thus,
HESs can be divided into primary (neoplastic) HES, second-
ary (reactive) HES, and idiopathic HES.
4–9 The ICOG-EO
group recommends that the term HES be reserved for such
clinical syndromes but not for underlying malignancy or auto-
immune disease associated with eosinophilia.
9 In primary
(neoplastic) HES or secondary HES, an underlying disease
is identiﬁed and is included in the ﬁnal diagnosis, for exam-
ple, chronic eosinophilic leukemia (CEL) with primary HES.
In contrast, a diagnosis of idiopathic HES implies the absence
of a known etiology.
Using this nosology, the term HES should be applied to
document and describe syndromes with eosinophil-induced
organ damage, irrespective of the presence of an underlying
etiology. In fact, the diagnosis of HES should prompt
physicians to investigate and search for underlying mecha-
nisms and disorders.
8,9 In previous WHO classiﬁcations, HES
was sometimes employed as a synonym of CEL and some-
times to discriminate CEL from other hematologic conditions/
neoplasms.
10–13 In the latest edition of the “WHO mono-
graph,”
12 the term “HES” is not recommended as a synonym
of WHO-deﬁned neoplasms. This distinction between HES
and the underlying disorder is in agreement with the proposal
of the ICON group.
9
The spectrum of nonneoplastic and neoplastic disorders
that can underlie HES is broad, and allergic disorders are often
important considerations in the differential diagnosis.
14–23
Molecular, immunological, and histopathological signs of clon-
ality of myeloid cells (eosinophils) as well as clinical and
laboratory features suggesting the presence of a reactive pro-
cess should be looked for in these patients.
14–18 Ad i a g n o s t i c
algorithm is shown in Figure 1. Among nonneoplastic (reac-
tive) disorders, common conditions such as helminth infections
or allergic diseases but also rare conditions and syndromes
have to be considered (Table 1).
19–23
It is noteworthy that blood hypereosinophilia (HE) is
not necessarily accompanied by organ damage (ie, criteria for
HES not fulﬁlled), even in the presence of an underlying
FIGURE 1. Diagnostic Algorithm in
patients with Eosinophilia. In a ﬁrst
step, the presence of eosinophilia or
hypereosinophilia (HE) is conﬁrmed.
Then, the etiology of eosinophilia / HE
is studied, and the patient is examined
for the presence of HE-related organ
damage. Based on results, patients are
classiﬁed into various hematologic or
immunologic diseases. In those who
are suffering from HE-related
organopathy, the additional diagnosis
of hypereosinophilic syndrome (HES)
is established. In a small proportion of
cases, familial HES or rare syndromes
presenting with HE, such as the Gleich
syndrome or Churg Strauss syndrome
(CSS), are diagnosed. L-HES,
lymphoid variant HES; EMS,
eosinophilia myalgia syndrome.
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9 This is espe-
cially true when HE is detected early in the disease process.
When a persistent (hyper)eosinophilia is demonstrated in
the absence of organ involvement or an underlying disease, the
(provisional) diagnosis of HE of uncertain signiﬁcance is
established.
9 Table 1 shows a summary of conditions associated
with HE.
DEFINITION AND CLASSIFICATION OF
HE-RELATED CONDITIONS AND DISORDERS
The diagnostic algorithm should start at the important
checkpoint of peripheral blood HE, deﬁned as a persistent
elevation of blood eosinophils above 1.5 · 109/L blood.
5–9 The
term “tissue HE” h a sa l s ob e e np r o p o s e da n dm a yb eu s e f u li nt h e
evaluation and classiﬁcation of HE-related disorders.
9 However,
the clinical impact of isolated tissue HE (without blood HE) is
difﬁcult to determine because robust data from large studies are
unavailable. In addition, documentation of tissue HE sometimes
requires special stains directed against eosinophil granule pro-
teins. Therefore, blood HE is considered the most important pri-
mary denominator and checkpoint when approaching HE-related
disorders.
1–13 In some patients, criteria for blood HE are not yet
met, but molecular and clinical signs are strongly indicative of
a particular eosinophilic disorder with or without an accompany-
ing HES. These patients should be followed closely because they
may progress to overt eosinophilic disease over time.
At the checkpoint HE, 2 critical questions have to be
answered to make a ﬁnal diagnosis: (1) is there an underlying
disease or condition and (2) are there clinical signs and
symptoms or laboratory abnormalities that point to the
presence of accompanying HE-induced organ damage
(HES)
9 (Figure 1). For example, the hematologic work up
reveals eosinophilic leukemia, and the staging investigations
show endomyocardial thrombosis/ﬁbrosis. The ﬁnal diagnosis
in this patient is CEL with primary HES. In such patients, with
HE and clinical manifestations that are typical of HES, histo-
pathology is rarely required for diagnosis. However, in cases of
rare or/and atypical organ manifestations (such as renal failure
or bloody diarrhea), tissue biopsy may be required to document
tissue HE and HE-induced organ damage, to establish the
diagnosis of HES. The demonstration of extensive extracellular
deposition of eosinophil-derived proteins, for example, eosin-
ophil major basic protein (MBP) supports the conclusion that
the organopathy is “HE-related.”
24–27
In patients with documented HE, 4 important groups of
underlying disorders (conditions) can be identiﬁed: (1) hema-
topoietic neoplasms, (2) other (nonhematopoietic) neoplasms
(paraneoplastic HE), (3) common allergic, reactive, or immu-
nologic conditions, and (4) rare clinically deﬁned syndromes
accompanied by HE, including rare inherited disorders.
Hematologic Neoplasms
Although many different hematologic disorders (neo-
plasms) can be accompanied by eosinophilia (Table 2), only
a few are consistently accompanied by clonal neoplastic
TABLE 1. Conditions associated with Hypereosinophilia (HE)
Reactive conditions
Helminth infections
Allergic reactions
Atopic diseases
Drug reactions (allergic or toxic)
Scabies, other infestations
Allergic bronchopulmonary aspergillosis
Autoimmune diseases
Other chronic inﬂammatory diseases
Chronic graft-vs-host disease
Lymphocytic/lymphoid variant HES
Neoplastic conditions involving the hematopoietic system (see Table 2)
Myeloid neoplasms
Mast cell neoplasms
Lymphoid neoplasms
Paraneoplastic conditions
Solid tumors/malignancy
Lymphoproliferative neoplasms
Idiopathic forms
Idiopathic eosinophilia
HE of uncertain (undetermined) signiﬁcance
Idiopathic HES
Rare syndromes associated with HE
Gleich syndrome
CSS
EMS
Omenn syndrome
Hyper IgE syndrome
Hereditary HE (not otherwise speciﬁed)
CSS, Churg-Strauss Syndrome; EMS, Eosinophilia Myalgia Syndrome.
TABLE 2. Hematopoietic Neoplasms Accompanied by
Eosinophilia
Neoplasms in which eosinophils are likely to be clonal cells
Acute eosinophilic leukemia
CEL
Acute myeloid leukemia with inv(16) (FAB AML M4eo)
Chronic myeloid leukemia
Myeloid neoplasms with PDGFR abnormalities (WHO types)
Hematopoietic neoplasms with FGFR1 abnormalities (WHO types)
Smoldering systemic mastocytosis
Aggressive systemic mastocytosis
Mast cell leukemia
Neoplasms in which eosinophils may or may not be part of the malignant
clone
Other MPN with eosinophilia*
MDS with eosinophilia
Other MDS/MPN overlap syndromes with eosinophilia*
Indolent systemic mastocytosis
Neoplasms in which eosinophils usually are not part of the malignant clone
Hodgkin disease
B- or T-cell non-Hodgkin lymphoma
Acute lymphoblastic leukemia
Chronic lymphocytic leukemia
Langerhans cell histiocytosis
*Other MPN or MPN/MDS: neoplasms where no abnormalities in the PDGFR or
FGFR1 genes are detectable.
CEL, chronic eosinophilic leukemia; PDGFR, platelet-derived growth factor
receptor; FGFR, ﬁbroblast growth factor receptor; MPN, myeloproliferative neoplasm
(s); MDS, myelodysplastic syndrome(s).
WHO, World Health Organization.
Valent et al WAO Journal  December 2012
176   2012 World Allergy Organization(primary) HE (HEN), and only very few neoplasms present
with HE plus HE-related organ damage, that is HES (HESN).
Myeloid neoplasms accompanied by HE (HEN) include the
rare variant of acute eosinophilic leukemia, the more common
chronic form of eosinophilic leukemia (CEL) that is often
associated with the FIP1L1-PDGFRA rearrangement and
endomyocardial thrombosis/ﬁbrosis (HESN), and other mye-
loid neoplasms with rearrangements involving PDGFRA,
PDGFRB,o rFGFR1, such as the 8p11 syndrome.
8–18,28–30
HEN may also accompany untreated Ph1 chronic myeloid
leukemia (Table 2). Rarely, HEN is found in patients with
myelodysplastic syndromes (MDS).
31 In most cases with dys-
plastic marrow and HE, additional signs of myeloproliferation
are found, consistent with a diagnosis of MDS/myeloprolif-
erative neoplasm (MPN) overlap disease or frank MPN.
8–13
This is also true for cases of HEN exhibiting either a PDGFR
or FGFR1 rearrangement. In other variants of MPN, MDS, or
MPN/MDS, eosinophilia is less commonly detected. Another
myeloid neoplasm that is often accompanied by HE is sys-
temic mastocytosis (SM)
32–34 (Table 2). Clonal eosinophilia
is frequently seen in advanced stages of SM, that is. aggres-
sive SM and mast cell leukemia, and many of these patients
develop HE (usually without HES).
33
Lymphoid neoplasms can also present with HE. In most
cases, T-cell lymphoma is diagnosed, and eosinophils are
nonclonal cells.
35–37 However, in patients with the 8p11 syn-
drome and a few other rare entities, both eosinophils and lym-
phocytes can be involved in the clonal neoplastic process.
16,38
Paraneoplastic Conditions Associated
With HE
Several different types of cancers can be accompanied by
(or even preceded by) eosinophilia.
39 In some patients, overt HE
or even HES may develop. Cancers associated with HE include
adenocarcinomas of the lung, gastrointestinal (GI) tract, pancreas,
and thyroid, gynecological tumors, and skin cancers.
39 Although
the pathogenesis remains unclear, a commonly accepted hypoth-
esis is that cancer cells or the cancer-related microenvironment
(eg, ﬁbroblasts) produce eosinophilopoietic cytokines.
Common Reactive/Immunologic Conditions
A number of different immunologic and other reactive
conditions can cause reactive HE (HER). These include infec-
tious diseases (eg, helminth infections, HIV, and certain fun-
gal infections), allergic disorders (eg, allergic asthma, food
allergy, atopic dermatitis, and drug reactions, including the
DRESS syndrome), and chronic inﬂammatory/autoimmune
disorders.
6,19,20,22,23,40 Although not routinely tested, increased
production of eosinophilopoietic cytokines in vitro by clonal
T lymphocytes and/or lymphocytes with an aberrant surface
phenotype can be documented in some cases of HER in the
absence of a T-cell lymphoma.
41–43 In such cases, HER-related
organ damage is often seen, conﬁrming the diagnosis of the
lymphoid variant of HES (L-HES).
4,37
Rare Syndromes Accompanied by HE
These include, among others, episodic angioedema and
eosinophilia (Gleich syndrome), Churg–Strauss syndrome
(CSS), Eosinophilia Myalgia syndrome (EMS), Omenn syn-
drome, and the Hyper-IgE syndrome (Table 1).
44–51 Gleich
syndrome is a disease characterized by recurrent angioedema
associated with blood eosinophilia and elevated serum IL-5
and IgM levels (polyclonal IgM).
4,44,45 In some of these
patients, lymphocyte phenotyping reveals an abnormal (acti-
vated) T-cell compartment (CD41 T cells with decreased or
absent membrane expression of CD3). Based on this observa-
tion, Gleich syndrome has also been regarded as a special
subvariant of L-HES. Typical features in patients with CSS
are a necrotizing vasculitis accompanied by asthma and eosin-
ophilia.
46–48 In a subgroup of these patients, antineutrophil
cytoplasmic antibodies are detectable. EMS is a condition
deﬁned by myalgia and eosinophilia, often accompanied by
neurological symptoms and skin abnormalities.
49–51 Epidemic
cases of EMS have been reported in the context of exposure to
contaminated L-tryptophan or rapeseed oil (toxic oil syn-
drome). Omenn syndrome and Hyper-IgE syndrome are rare
inherited immunodeﬁciency syndromes presenting with eosin-
ophilia. There are also other clinical conditions and syndromes
that may present with HE and resemble HES. In many of these
conditions, eosinophilia is triggered by aberrantly produced
eosinophilopoietic growth factors, such as IL-5 or GM-CSF.
PREVALENCE AND EPIDEMIOLOGIC FEATURES
To date, little is known about the incidence and
prevalence of HE and HES or the frequency and incidence
of neoplastic and nonneoplastic conditions underlying HE
and HES.
52 This is due to the rarity of these conditions, poor
general knowledge about disease variants, and recent techno-
logical advances that have led to the identiﬁcation of several
(potentially) underlying pathogenic mechanisms, clinical
correlates, and drug targets during the last 10 years. The
epidemiological features of HE and HES are also poorly
understood. Some eosinophil-related neoplasms show a clear
gender prevalence, such as PDGFRA-rearranged CEL, which
afﬂicts males in the vast majority of cases,
53 whereas in other
leukemias accompanied by eosinophilia, no obvious gender
predominance has been described.
PATHOPHYSIOLOGY
The degree and pattern of organ involvement in
eosinophilic disorders are governed by 2 distinct factors. The
ﬁrst is the increased production and/or persistent accumulation
of (normal or neoplastic) eosinophils that leads to HE and
predisposes to or triggers the development of HES (high
effector cell burden). The second factor is (persistent) “activa-
tion of eosinophils,” which is responsible for the clinical man-
ifestations of HES. In many instances, both eosinophilia and
eosinophil activation are present and have similar (or the same)
underlying causes (eg, eosinophil-targeting cytokines). In other
cases, HE may persist for many years without evidence of
eosinophil activation or clinical manifestations.
9
Several basic mechanisms can lead to the persistent
accumulation of eosinophils in blood and tissues, including
increased proliferation and/or survival of eosinophil-committed
progenitor cells, and enhanced survival of mature eosinophils. In
WAO Journal  December 2012 ICON: Eosinophil Disorders
  2012 World Allergy Organization 177principle, 2 pathogenetically different conditions can trigger
eosinophil growth and accumulation, namely (1) an intrinsic
defect of eosinophil-committed neoplastic progenitor cells,
caused by mutations including those involving PDGFR or
FGFR1, and (2) overproduction of cytokines, such as IL-3 or
IL-5, that stimulate the growth, differentiation, and survival of
(normal or neoplastic) eosinophils and eosinophil precursor
cells.
40,54,55 Although in most cases, only one of these two
pathologic mechanisms may contribute to the development of
HE, there are patients in whom neoplastic eosinophils have been
described to produce autocrine eosinophil growth factors (IL-3,
IL-5) themselves Furthermore, overproduction of HE-promoting
cytokines may stem from another (noneosinophilic) clonal pro-
cess such as a T-cell lymphoma or the L-HES.
4,37
As mentioned above, eosinophil activation is often
triggered by the same or similar factors that induce HE.
Likewise, most of the eosinophilopoietic cytokines, including
IL-3 and IL-5, induce activation and tissue homing of mature
blood eosinophils.
56–58 It is also well known that neoplastic
eosinophils that derive from PDGFR-rearranged clonal
precursor cells are in an “activated state”
59 and often cause
HES-related organ damage. Nevertheless, not all patients with
HE develop HES consistent with a multifactorial pathogene-
sis of end-organ damage in eosinophilic diseases.
Little is known about the role of eosinophil-derived
mediators and molecules in the development of HES-related
organ damage. Eosinophils are a rich source of various
proinﬂammatory mediators and cytokines, including growth
factors and chemotactic peptides and vasoactive, proﬁbrotic,
and angiogenic molecules.
60–65 In addition, eosinophils produce
various lipid mediators and cytotoxic proteins, including eosin-
ophil cationic protein (ECP), eosinophil major basic proteins
(MBP1 and MBP2), eosinophil peroxidase (EPO), and eosino-
phil-derived neurotoxin (EDN).
64–67 Eosinophil-derived peptide
mediators and cytokines have diverse biological properties.
Some of these proteins are directly toxic to cells and micro-
organisms,
65–67 whereas others act indirectly by activating var-
ious immune and nonimmune cells. Together, these mediators
and substances, when released from activated eosinophils, can
cause tissue remodeling and/or tissue damage. Eosinophil prod-
ucts can also activate platelets and endothelial cells and alter the
production/expression of prothrombotic and antiﬁbrinolytic
substances, contributing to tissue ﬁbrosis and thrombosis.
CLINICAL MANIFESTATIONS AND DIAGNOSIS
Depending on the type of disease and other factors,
a number of different organ systems may be involved in
patients with HES. The most commonly involved organs are
the skin, lungs, GI tract, heart, and the central nervous system.
In some patients, the relationship between the eosinophilia
and typical clinical signs and symptoms are pathognomonic,
whereas in others tissue biopsy may be required to document
eosinophilia and tissue HE.
Endomyocardial thrombosis and ﬁbrosis are often docu-
mented in primary (neoplastic) HES (HESN), particularly in asso-
ciation with the FIP1L1-PDGFRA fusion gene, but are also seen
in other variants of HES.
68–70 A thorough cardiac evaluation
including an electrocardiogram and echocardiogram is
mandatory in all patients with HE. Cardiac magnetic resonance
imaging is helpful in distinguishing eosinophilic cardiac disease
from that of other etiologies. In some cases, troponin levels may
also be helpful. An endomyocardial biopsy may be required in
some cases for deﬁnitive diagnosis but is usually not performed.
The presence of eosinophils in the myocardium is always abnor-
mal and highly suggestive of eosinophil-mediated organopathy.
In addition, the biopsy may reveal local thrombosis and ﬁbrosis.
The respiratory system is commonly involved in HES.
71,72
To conﬁrm that respiratory manifestations are related to HE,
a number of studies can be helpful, including pulmonary func-
tion tests, chest radiography and/or computed tomography scan,
and bronchoscopy with bronchoalveolar lavage and tissue
biopsy if necessary. The differential diagnosis of HESR with
pulmonary involvement includes drug allergy, anti-neutrophil
cytoplasmic antibodies–-negative CSS, chronic eosinophilic
pneumonia, severe allergic bronchial asthma with eosinophilia,
allergic bronchopulmonary aspergillosis, and other eosinophilic
lung infections.
An important biomarker for asthma control and response
to therapy is induced sputum eosinophilia. This ﬁnding has
proven to be a useful and consistent marker of inﬂammation in
asthma at all levels of severity and control.
73,74
The evaluation of skin involvement in HES is a clinical
and histopathologic challenge.
72,75 Consequently, an experi-
enced dermatologist should be involved in making the diagno-
sis of HES on the basis of skin involvement. HES may be
associated with a large spectrum of dermatologic manifesta-
tions, including papules, eczema, angioedema, urticaria, eryth-
rodermia, mucosal (oral and genital) ulcers, and necrotizing
vasculitis. In some patients, skin lesions may be severe and
debilitating despite therapy.
The bone marrow is frequently affected in HES. In
idiopathic HES and HESR, there is usually a mild to moderate
tissue eosinophilia without alteration of the bone marrow
microarchitecture and without abnormalities in other hemato-
poietic lineages. In contrast, in HESN, there is often marked
tissue eosinophilia leading to substantial hypercellularity in
the bone marrow and alteration of its microarchitecture. Other
hematopoietic lineages show typical aberrations according to
the underlying hematopoietic neoplasm, which might be an
MPN, MDS, MDS/MPN overlap disease, acute myeloid leu-
kemia (AML), or, rarely, a lymphoid neoplasm (Table 2). In
these patients, various blood count abnormalities may be
present, such as thrombocytosis, monocytosis, basophilia,
and a left shift or/and a slight increase in blast cells. In some
cases, an advanced myeloid neoplasm may be detected. In
other cases, anemia or/and thrombocytopenia with or without
increased blast cells or dysplasia is found, consistent with the
diagnosis of an MDS, MDS/MPN overlap disease, or (pri-
mary or secondary) AML. In rare cases, stem cell disease with
involvement of the myeloid and lymphoid lineage is identi-
ﬁed. In some of these patients, the 8p11 syndrome is diag-
nosed. The prognosis is poor in these patients.
GI tract involvement is common in HES,
72,76,77 partic-
ularly in patients with HESR or the idiopathic form of HES. In
these patients, a wide variety of symptoms and ﬁndings have
been described, including abdominal pain, vomiting, chronic
diarrhea, or chronic ulcerative disease.
72,77
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Patients with HE without symptoms may not require any
therapy. However, in case of organ damage (HES), treatment
has to be initiated. The type of therapy varies depending on the
underlying condition and type of HES. Reactive HES is best
managed by treating the underlying disease.
78–80 In patients
with primary (neoplastic) HE or HES, speciﬁct h e r a p yw i t h
targeted drugs or chemotherapy may be required. If the under-
lying disease is resistant, eosinophil counts can usually be kept
under control with hydroxyurea or interferon alpha (IFN-a).
For patients with idiopathic HES or L-HES, glucocorticoids are
often prescribed.
78–80 However, chronic use of glucocorticoids
is often associated with substantial side effects. Currently avail-
able corticosteroid-sparing agents that can be used in these
patients include hydroxyurea and IFN-a.
78–80 Mepolizumab,
a humanized anti-IL-5 antibody, has also been shown to be
a safe and effective steroid-sparing agent in patients with non-
neoplastic (steroid-responsive) HES,
81,82 and in patients with
asthma and CSS. However, the drug is currently unavailable
for use in clinical practice.
In contrast to patients with idiopathic HES and HESR,
patients with HESN typically respond only partially or tran-
siently to glucocorticoid therapy. IFN-a and hydroxyurea
have been used with some success in patients with HESN.
However, in patients with rearranged PDGFRA or
PDGFRB, imatinib is usually effective and is thus used as
standard ﬁrst-line therapy.
83–86 Based on the potent activity of
this kinase blocker in such patients, it is essential to search for
and deﬁne these molecular defects in all patients with sus-
pected CEL or HESN.
The most frequent fusion oncoprotein and target detect-
able in patients with HESN (usually in CEL patients) is FIP1L1-
PDGFRA.
84–87 This oncogenic gene product is a target of
imatinib and is also sensitive to other tyrosine kinase inhibitors
(TKIs), such as nilotinib or dasatinib. Other molecular targets of
imatinib are also detectable in patients with HESN (including
CEL), albeit at lower frequency. Most of these fusion genes
involve PDGFRA or PDGFRB.B yc o n t r a s t ,F G F R 1f u s i o n
proteins are resistant both to imatinib and to most other TKIs.
For patients with FIP1L1-PDGFRA1 disease, imatinib
is now considered standard ﬁrst-line treatment. Most patients
have a long-lasting response to this drug. The recommended
starting dose is usually 100 to 400 mg daily, and in the major-
ity of patients, remission is maintained with low-dose treatment
(100 mg daily), although some patients may require 400 mg
daily to keep the eosinophil counts under control.
84–88 Primary
and secondary resistance to imatinib occurs, but is uncommon,
and is generally caused by rare mutations in FIP1L1-PDGFRA.
Newer TKIs, such as sorafenib, nilotinib, midostaurin, and
ponatinib, are an option in the setting of drug resistance (as
experimental agents, in clinical trials). Another approach is the
use of alternative cytoreductive agents, such as IFN-a,
hydroxyurea, or polychemotherapy. In patients who progress
to AML or who have resistant disease with life-threatening
clinical manifestations, high-dose chemotherapy and hemato-
poietic stem cell transplantation must be considered.
In most patients with FGFR1-derived fusion proteins,
imatinib is ineffective and thus is not recommended.
86,87 In
many of these patients, the condition behaves as an aggressive
stem cell disease or a leukemia/lymphoma syndrome, also
known as 8p11 syndrome. In these patients, chemotherapy
with consecutive allogeneic stem cell transplantation is usu-
ally recommended. An alternative may be the use of novel
more potent TKI, such as ponatinib.
UNMET NEEDS
There are several unmet needs in the ﬁeld of eosinophil
disorders, not only in terms of basic and applied science and
in the management of disease variants but also with respect to
terminologies, classiﬁcation, and prognostication. These issues
should be addressed in a comprehensive and multidisciplinary
way, which is the main goal of the recently established ICOG-
EO working group. With regard to classiﬁcations, it is
important to separate the clinical syndrome HES and HES-
deﬁning criteria from criteria and deﬁnitions used to establish
the ﬁnal diagnosis of an underlying neoplastic (hematologic) or
nonneoplastic disease. A good example of a similar situation is
lymphoma, where B symptoms (eg, weight loss or fever) may
be recorded based on deﬁned criteria, but these criteria are not
used in the histopathologic diagnosis of the lymphoma. Thus,
a given lymphoma may or may not present with B symptoms.
Similarly, eosinophil disorders may or may not present with
HE-related organ damage (HES). Another unmet need is to
validate all new classiﬁcation proposals, including the proposal
of the ICOG-EO working group. Notably, several different
new criteria, provided by the WHO, ICOG-EO, or other
groups, are based primarily on expert opinion rather than on
robust studies. There is of course published evidence support-
ing each of these newly proposed terms or criteria, but only
robust global validation will lead to broad acceptance and
proper application of the criteria in clinical practice. In this
regard, large (global) registries and trials must be established,
wherein even rare subcategories of eosinophil disorders can be
analyzed in terms of their incidence, prevalence, disease
course, prognosis, and treatment response.
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